NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper Buys 2,520 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director James N. Topper acquired 2,520 shares of the company's stock in a transaction on Tuesday, June 24th. The stock was acquired at an average price of $18.43 per share, with a total value of $46,443.60. Following the purchase, the director now directly owns 3,024,873 shares in the company, valued at approximately $55,748,409.39. This represents a 0.08% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

NewAmsterdam Pharma Trading Up 0.7%

NewAmsterdam Pharma stock traded up $0.12 during midday trading on Thursday, reaching $18.45. The stock had a trading volume of 755,738 shares, compared to its average volume of 707,775. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $27.29. The firm's 50-day moving average price is $18.64 and its 200 day moving average price is $20.80.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). The company had revenue of $2.98 million for the quarter, compared to the consensus estimate of $1.46 million. NewAmsterdam Pharma had a negative net margin of 397.45% and a negative return on equity of 37.34%. As a group, research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Cantor Fitzgerald started coverage on NewAmsterdam Pharma in a report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 target price on the stock. Scotiabank increased their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 27th. Wall Street Zen cut NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a research note on Saturday, June 21st. Citigroup began coverage on NewAmsterdam Pharma in a report on Tuesday, June 17th. They set a "buy" rating and a $42.00 price target for the company. Finally, UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a research report on Monday, March 3rd. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $42.89.

Hedge Funds Weigh In On NewAmsterdam Pharma

Institutional investors have recently made changes to their positions in the stock. Deerfield Management Company L.P. Series C raised its holdings in shares of NewAmsterdam Pharma by 378.4% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company's stock valued at $110,879,000 after buying an additional 3,412,590 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its stake in NewAmsterdam Pharma by 23.8% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company's stock worth $409,052,000 after purchasing an additional 3,061,224 shares during the last quarter. Wellington Management Group LLP boosted its position in NewAmsterdam Pharma by 2,410.4% during the fourth quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock valued at $59,499,000 after buying an additional 2,222,900 shares during the period. Capital International Investors bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at about $53,007,000. Finally, Alliancebernstein L.P. bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at about $47,752,000. Institutional investors own 89.89% of the company's stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.